Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-09-12)Premium Content

Biomarin Pharmac. (BMRN)

2014-09-16@13:43:03 ET
BioMarin Pharmaceutical (BMRN) Showing Neutral Technicals (FBM)

2014-09-15@18:09:53 ET
SmarTrend Watching for Potential Rebound in Shares of BioMarin Pharmaceutical After 1.78% Loss (PSM)

2014-09-15@14:02:10 ET
BioMarin Pharmaceutical Shares Sinking Lower, Down 2.3% (F77)

2014-09-15@09:09:17 ET
BioMarin Pharmaceutical (BMRN) Showing Resistance Near $69.70 (FBM)

2014-09-15@08:00:24 ET
BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines (PMZ)

2014-09-12@13:40:26 ET
BioMarin Pharmaceutical (BMRN) Trading Near $69.71 Resistance Level (FBM)

2014-09-12@04:42:08 ET
Global Batten Disease Therapeutics Pipeline Review 2014 - 2 Companies & 5 Drug Profiles (MTO)

2014-09-11@12:23:07 ET
BioMarin Pharmaceutical Crosses Below its 10-day MA (BMRN) (F78)

2014-07-23@13:34:03 ET
BioMarin Pharmaceutical (BMRN) Showing Neutral Technicals (FBM)

2014-07-23@08:00:36 ET
Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation (PMZ)

2014-07-22@11:20:19 ET
BioMarin Pharmaceutical (BMRN) Showing Bearish Technicals With Support At $57.34 (FBM)

2014-07-21@12:42:22 ET
Shares of BioMarin Pharmaceutical Under Pressure, Down 1.8% (F77)

2014-07-21@10:22:32 ET
BioMarin Pharmaceutical (BMRN) Showing Support Near $54.59 (FBM)

2014-07-17@16:31:39 ET
Potential BioMarin Pharmaceutical (BMRN) Trade Targets 7.97% Return (FBM)

2014-07-17@08:40:00 ET
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept (PRN)

2014-07-16@12:04:03 ET
Potential BioMarin Pharmaceutical (BMRN) Trade Has 10.75% Downside Protection (FBM)

2014-07-15@18:45:27 ET
SmarTrend Watching for Potential Rebound in Shares of BioMarin Pharmaceutical After 2.35% Loss (PSM)